Skip to content
10-Q

Quarterly Report

Royalty Pharma plc RPRX

0001802768-26-000009

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 556.84M sh
Shares Diluted Q1 2026 · Mar 31, 2025 578.1M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $50.1M
Stock Repurchased Q1 2026 · Mar 31, 2025 $708.78M
Operating Cash Flow Q1 2026 · Mar 31, 2026 $718.23M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $596.08M
Long Term Debt Q1 2026 · Mar 31, 2026 $8.58B
Long Term Debt Q1 2026 · Dec 31, 2025 $8.57B
Short Term Debt Q1 2026 · Mar 31, 2026 $380M
Short Term Debt Q1 2026 · Dec 31, 2025 $380M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $586.4M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $618.7M
Stockholders Equity Q1 2026 · Mar 31, 2026 $9.94B
Stockholders Equity Q1 2026 · Dec 31, 2025 $9.71B
Stockholders Equity restated Q1 2026 · Mar 31, 2025 $9.78B
Stockholders Equity Q1 2026 · Dec 31, 2024 $10.34B
Current Liabilities Q1 2026 · Mar 31, 2026 $535.68M
Current Liabilities Q1 2026 · Dec 31, 2025 $636.21M
Total Liabilities Q1 2026 · Mar 31, 2026 $9.88B
Total Liabilities Q1 2026 · Dec 31, 2025 $9.91B
Current Assets Q1 2026 · Mar 31, 2026 $1.43B
Current Assets Q1 2026 · Dec 31, 2025 $1.53B
Total Assets Q1 2026 · Mar 31, 2026 $19.82B
Total Assets Q1 2026 · Dec 31, 2025 $19.62B
Eps Diluted Q1 2026 · Mar 31, 2026 $0.67
Eps Diluted Q1 2026 · Mar 31, 2025 $0.55
Eps Basic Q1 2026 · Mar 31, 2026 $0.67
Eps Basic Q1 2026 · Mar 31, 2025 $0.55
Sga Expense Q1 2026 · Mar 31, 2026 $159.49M
Sga Expense Q1 2026 · Mar 31, 2025 $110.71M
Rd Expense Q1 2026 · Mar 31, 2026 $39.79M
Rd Expense Q1 2026 · Mar 31, 2025 $50.5M
Net Income Q1 2026 · Mar 31, 2026 $294.69M
Net Income restated Q1 2026 · Mar 31, 2025 $239.35M
Operating Income Q1 2026 · Mar 31, 2026 $563.04M
Operating Income Q1 2026 · Mar 31, 2025 $534.18M
Revenue Q1 2026 · Mar 31, 2026 $630.58M
Revenue Q1 2026 · Mar 31, 2025 $568.25M